Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CSL Reports Profits Up 63 Percent for FY 2009; Swine Flu Data Expected Next Month

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Melbourne-headquartered CSL reported this week that it posted AU$1.15 billion ($943 million) in net profits for FY2009, up 63 percent year on year. With cash flow from operations of AU$1.03 billion, the company is well positioned for an alternative acquisition target after scuttling its $3.1 billion merger with U.S.-based Talecris

Related Content

UsernamePublicRestriction

Register

SC072517

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel